Enliven Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Enliven Therapeutics

13/08/2024 23:02

* Enliven Therapeutics Inc  ELVN.OQ  reported a quarterly
adjusted
loss of 41 cents​​ per share for the quarter ended in June,
identical to the same quarter last year.  The mean expectation
of six analysts for the quarter was for a loss of 55 cents per
share. Wall Street expected results to range from -65 cents
to -49 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Enliven Therapeutics Inc's reported EPS for the quarter
was a
loss of 41 cents​.
    * The company reported a quarterly loss of $19.95 million.
    * Enliven Therapeutics Inc shares had fallen by 8.8% this
quarter and gained 54.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Enliven
Therapeutics Inc is $33.00 
This summary was machine generated from LSEG data August 13 at
10:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.55          -0.41          Beat
 Mar. 31 2024      -0.57          -0.54          Beat
 Dec. 31 2023      -0.54          -0.47          Beat
 Sep. 30 2023      -0.47          -0.51          Missed